CC
CRL icon

Carlson Capital’s Charles River Laboratories CRL Stock Holding History

Carlson Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-163,568
Closed -$16.5M – 230
2017
Q2 		$16.5M Buy
163,568
+30,750
+23% +$2.83M 0.24% 129
2017
Q1 		$11.9M Buy
+132,818
New +$11.3M 0.15% 176

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carlson Capital's CRL Position: Q3 2017 in Review

Carlson Capital sold out of Charles River Laboratories (CRL) in Q3 2017, closing a stake of 163,568 shares — an estimated $16.5M sold.

Carlson Capital first reported a position in CRL in Q1 2017 and held it in 2 quarters. The position peaked at $16.5M in Q2 2017. 336 funds tracked by Wall St. Rank hold CRL as of Q3 2017.

  • Carlson Capital reported no remaining Charles River Laboratories position as of Q3 2017 after selling out during the quarter.
  • Carlson Capital sold 163,568 Charles River Laboratories shares in Q3 2017, an estimated $16.5M.
  • Carlson Capital first reported a position in Charles River Laboratories in Q1 2017 and held it in 2 quarters.
  • Carlson Capital's Charles River Laboratories position peaked at $16.5M in Q2 2017.
  • 336 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2017.

Based on Carlson Capital's 13F filing for Q3 2017, filed 14 Nov 2017.